To the Editor In the updated Recommendations of the International Antiviral Society–USA Panel for the treatment and prevention of human immunodeficiency virus (HIV) infection in adults,1 the recommendations for laboratory monitoring have been revised to include the use of baseline HIV genotype to assess transmitted drug resistance. The panel recommended testing only for nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors, and reserved testing for integrase strand-transfer inhibitor (InSTI) resistance to cases of suspected exposure to a partner with InSTI resistance. All preferred regimens are InSTI-based, favoring dolutegravir and bictegravir and, when those are not available, raltegravir and elvitegravir/cobicistat.1
Ambrosioni J, Mosquera M, Miró JM. Baseline Genotype Testing to Assess Drug Resistance Before Beginning HIV Treatment. JAMA. 2018;320(20):2153–2154. doi:10.1001/jama.2018.15926
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: